Table 2.

Enrichment results obtained from the application to the Connectivity Map to 5 different data sets defining MSI CRCs

Data setCompound nameDose (μM)Cell lineConnectivity scoreEnrichment score
VilarPhenanthridinone51MCF7−0.68−0.98
BanerjeaPhenanthridinone51MCF7−0.61−0.94
WatanabePhenanthridinone51MCF700.62
KoinumaPhenanthridinone51MCF7−0.60−0.95
KruhofferPhenanthridinone51MCF700.54
VilarNU-1025100MCF700.523
BanerjeaNU-1025100MCF7−0.243−0.4
WatanabeNU-1025100MCF7−0.56−0.93
KoinumaNU-1025100MCF700.408
KruhofferNU-1025100MCF70.460.81
Vilar1,5-Isoquinolinediol100HL6000.650
Banerjea1,5-Isoquinolinediol100HL60−0.51−0.86
Watanabe1,5-Isoquinolinediol100HL600−0.642
Koinuma1,5-Isoquinolinediol100HL600−0.53
Kruhoffer1,5-Isoquinolinediol100HL6000.656

NOTE. Enrichment and connectivity scores for every data set are presented. These scores are intended to reflect the correlation between gene expression changes induced in cell line models after treatment with first-generation PARP-1 inhibitor and those gene expression profiles characterizing MSI-H tumors coming from different data sets. The enrichment score indicates the strength of this correlation and the connectivity score is relative to the rest of drugs tested in the Connectivity Map. The absolute value of both ranges from +1 to −1 and refers to the level of correlation or anticorrelation with the original signature of interest. Phenanthridinone, NU-1025, and 1,5-Isoquinolinediol are first-generation PARP inhibitors, with phenanthridinone being the compound with the most consistent results.